3-tyr-octreotide has been researched along with Carcinoma, Neuroendocrine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, RP; Bitterlich, N; Kluge, AW; Kulkarni, H; Niepsch, K; Schorr-Neufing, U; van Echteld, CJ | 1 |
1 trial(s) available for 3-tyr-octreotide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Topics: Aged; Carcinoma, Neuroendocrine; Female; Humans; Lutetium; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |